tetano
Editor, Senior Moderator
Obes Facts
. 2020 Aug 13;1-14.
doi: 10.1159/000510719. Online ahead of print.
Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity
Gijs H Goossens[SUP] 1 2 [/SUP], Dror Dicker[SUP] 3 4 [/SUP], Nathalie J Farpour-Lambert[SUP] 3 5 [/SUP], Gema Fr?hbeck[SUP] 3 6 [/SUP], Dana Mullerova[SUP] 3 7 [/SUP], Euan Woodward[SUP] 3 8 [/SUP], Jens-Christian Holm[SUP] 3 9 [/SUP]
Affiliations
Abstract
Accumulating evidence suggests that obesity is a major risk factor for the initiation, progression, and outcomes of coronavirus disease 2019 (COVID-19). The European Association for the Study of Obesity (EASO), as a scientific and medical society dedicated to the promotion of health and well-being, is greatly concerned about the concomitant obesity and COVID-19 pandemics and their impact on health and society at large. In this perspective, we will address the inherent immunological perturbations and alterations in the renin-angiotensin-aldosterone system in patients with obesity and COVID-19, and discuss how these impairments may underlie the increased susceptibility and more detrimental outcomes of COVID-19 in people with obesity. Clearly, this has important implications for preventive measures, vaccination, and future therapeutic strategies to combat COVID-19. Furthermore, we will highlight important knowledge gaps and provide suggestions for future research and recommendations for policy actions. Since many new reports on COVID-19 rapidly appear, the present perspective should be seen as a focus for discussion to drive forward further understanding, research initiatives, and clinical management of COVID-19.
Keywords: ACE2; COVID-19; Coronavirus disease 2019; Immune response; Obesity; Renin-angiotensin-aldosterone system; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2.
. 2020 Aug 13;1-14.
doi: 10.1159/000510719. Online ahead of print.
Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity
Gijs H Goossens[SUP] 1 2 [/SUP], Dror Dicker[SUP] 3 4 [/SUP], Nathalie J Farpour-Lambert[SUP] 3 5 [/SUP], Gema Fr?hbeck[SUP] 3 6 [/SUP], Dana Mullerova[SUP] 3 7 [/SUP], Euan Woodward[SUP] 3 8 [/SUP], Jens-Christian Holm[SUP] 3 9 [/SUP]
Affiliations
- PMID: 32791497
- DOI: 10.1159/000510719
Abstract
Accumulating evidence suggests that obesity is a major risk factor for the initiation, progression, and outcomes of coronavirus disease 2019 (COVID-19). The European Association for the Study of Obesity (EASO), as a scientific and medical society dedicated to the promotion of health and well-being, is greatly concerned about the concomitant obesity and COVID-19 pandemics and their impact on health and society at large. In this perspective, we will address the inherent immunological perturbations and alterations in the renin-angiotensin-aldosterone system in patients with obesity and COVID-19, and discuss how these impairments may underlie the increased susceptibility and more detrimental outcomes of COVID-19 in people with obesity. Clearly, this has important implications for preventive measures, vaccination, and future therapeutic strategies to combat COVID-19. Furthermore, we will highlight important knowledge gaps and provide suggestions for future research and recommendations for policy actions. Since many new reports on COVID-19 rapidly appear, the present perspective should be seen as a focus for discussion to drive forward further understanding, research initiatives, and clinical management of COVID-19.
Keywords: ACE2; COVID-19; Coronavirus disease 2019; Immune response; Obesity; Renin-angiotensin-aldosterone system; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2.